Details for Patent: 6,455,518

Summary for Patent: 6,455,518

Title:	Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
Abstract:	A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
Inventor(s):	Zenke; Gerhard (Rheinfelden, DE), Schuurman; Hendrik (Basel, CH), Haeberlin; Barbara (Riehen, CH), Meinzer; Armin (Buggingen, DE)
Assignee:	Novartis AG (Basel, CH)
Application Number:	09/758,301
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,455,518
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation; Use; Dosage form; Device;

Drugs Protected by US Patent 6,455,518

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,455,518

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9615942	Jul 30, 1996
United Kingdom	9705684	Mar 19, 1997

International Family Members for US Patent 6,455,518

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	222502
Austria	340586
Australia	4012497
Australia	730781
Canada	2261666